menu
    • menu
    [{"orgOrder":0,"company":"RareStone Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves RareStone's Pitolisant (Wakix) for the Treatment of Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"RareStone Group","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"RareStone Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RareStone Group \/ Not Applicable"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RareStone Inc. Announces Submission of New Drug Application (NDA) of Wakix\u00ae (pitolisant) for narcolepsy with and without cataplexy in China","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"RareStone Group","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"RareStone Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RareStone Group \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by RareStone Group

    Menu

    RareStone Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RareStone Group

                            China arrow
                            Luxepack
                            Not Confirmed

                            RareStone Group

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            China NMPA Approves RareStone's Pitolisant (Wakix) for the Treatment of Narcolepsy

                            Details : Wakix (pitolisant) is a selective histamine 3 (H3) receptor antagonist/inverse agonist, which was granted orphan drug designation for the treatment of narcolepsy by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

                            Brand Name : Wakix

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 04, 2023

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RareStone Group

                            China arrow
                            Luxepack
                            Not Confirmed

                            RareStone Group

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RareStone Inc. Announces Submission of New Drug Application (NDA) of Wakix® (pitolisant) for narcolepsy with ...

                            Details : Wakix (pitolisant hydrochloride), a selective histamine H3-receptor antagonist/inverse agonist, is approved by the EMA and the FDA to treat adults suffering from narcolepsy, a serious, chronic disorder characterized by excessive daytime sleepiness, with ...

                            Brand Name : Wakix

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 21, 2021

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth